Skip to main content
Clinical Trials/NCT00731900
NCT00731900UnknownNot Applicable

Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction

National Taiwan University Hospital1 site in 1 country100 target enrollmentStarted: April 2007Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
100
Locations
1

Study Overview

Brief Summary

Topiramate (TPM) is an antiepileptic drug with a unique mode of action that is often useful in patients refractory to other drugs. However its use is restricted by the high incidence of cognitive adverse drug reactions (ADRs) that are associated with TPM exposure. TPM has been shown to cause particular cognitive ADRs, characterized by verbal fluency, attention, working memory and language deficits, at a much higher rate than other antiepileptic drugs. There do not appear to be obvious differences between patients that do or do not experience cognitive ADRs when on TPM (e.g. age, sex, concomitant medications, diagnosis), which suggests a genetic contributor.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
17 Years to 70 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • adult (>17 years old) patients with epilepsy or patients with migraine treated by topiramate

Exclusion Criteria

  • allergy to topiramate
  • abnormal liver or renal function

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials